Vertex raises 2026 revenue guidance, reports Crinetics deal close and povetacicept PDUFA dateNov 2Quarterly updatepovetaciceptVertex Pharmaceuticals Inc / Ma
Vertex registers Phase 3b trial comparing povetacicept and sibeprenlimab in IgA nephropathyOct 22Trial updatepovetaciceptsibeprenlimab
Vertex registers Phase 1 VX-581 tablet study; adds detail on povetacicept IgAN extensionSep 10Weekly roundup, 2 itemspovetaciceptVertex Pharmaceuticals Inc / Ma
Vertex raises 2026 revenue guidance, sets povetacicept PDUFA date and Crinetics deal timingAug 3Quarterly updatepovetaciceptVertex Pharmaceuticals Inc / Ma